Ispire Technology Inc., a Nasdaq-listed company based in California, has obtained Malaysia’s first federal nicotine manufacturing license. This interim license allows Ispire to manufacture nicotine products in the country, positioning it as the sole company with federal authorization for the export, import, and production of such products.
The license was approved by both federal and state authorities in May 2024, enabling Ispire to commence manufacturing nicotine products immediately at its facility in Senai, Johor. Ispire plans to expand its production capabilities from the current six lines to 80 lines, aiming to meet growing market demand.
Michael Wang, co-CEO of Ispire Technology, emphasized the importance of this license for the company’s strategy as it seeks to establish itself as a leading provider of vaping hardware internationally. The company anticipates that once the final license is granted in the coming months, it will complete its regulatory requirements in Malaysia, solidifying its position in the market.
Ispire’s manufacturing facility spans 86,000 square feet, nearly three times the size of its initial production space, and is equipped to produce 61 million vaping devices or 107 million pods monthly. This expansion is designed to help Ispire avoid tariffs imposed on Chinese imports, thereby stabilizing pricing for customers.
In a bid to adapt to the ongoing trade tensions, Ispire has shifted its manufacturing operations from China to Malaysia. This relocation allows the company to provide high-quality products at competitive prices while reducing reliance on Chinese manufacturing.
Ispire’s operations extend beyond nicotine products; the company is also involved in the research, development, and sale of cannabis vaping products. Their cannabis products are marketed under the Ispire brand and sold primarily in the United States. The company adopts a business-to-business model, with distributors selling products to wholesalers and retailers.
The manufacturing facility in Johor is certified under ISO standards, which enhances its reputation in the global market. In February 2024, Ispire announced the opening of its ISO- and GMP-certified vape manufacturing facility, which produces a range of vaping products including vaporizers, cartridges, and batteries. The facility is designed to align with international quality standards and to facilitate access to global markets.
Despite the positive developments for Ispire, the regulatory landscape for vaping and cannabis products in Malaysia remains complex. The Malaysian government classifies cannabis as a dangerous drug under the Dangerous Drugs Act 1952, and the production of cannabis-related devices for local consumption is still ambiguous. The Malaysian Medical Device Authority has not recognized vape products as medical devices, which could impact the legality of cannabis vaporizer production in the country.
In recent months, anti-tobacco advocates have called for a federal ban on e-cigarettes, expressing concerns about the rise of vaping among youth and the potential for illicit drug adulteration. However, Ispire’s interim license allows it to operate within the current regulatory framework, even as local authorities have previously restricted retail licenses for vaping products.
The approval of this license comes at a time when Malaysia is gaining recognition for its commitment to reducing tobacco-related health issues. The Health Ministry’s recent accolades, including the World Health Organization’s World No Tobacco Day award, reflect the nation’s efforts to combat nicotine addiction.
Ispire’s strategic move into Malaysia’s vaping market signifies its ambition to capitalize on emerging opportunities while addressing the challenges posed by international trade dynamics. The company’s growth strategy includes enhancing its product lines and expanding its manufacturing capabilities to meet the demands of a rapidly evolving industry.
German 
English 
Spanish 
Czech